KEAP1 mutations are commonly concurrent with KRAS and/or STK11 mutations in NSCLC and confer tolerance to oxidative stress through the KEAP1/NRF2 pathway, promoting tumor progression and drug resistance (24–26). Here, KEAP1 is linked to neoplasm.